期刊
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY
卷 24, 期 7, 页码 731-770出版社
SPRINGER JAPAN KK
DOI: 10.1007/s10147-019-01431-z
关键词
Non-small cell lung cancer; Chemotherapy; Kinase inhibitor; Programed cell death-1 inhibitor; Programed death-ligand 1 inhibitor; Guideline
类别
资金
- Japanese Lung Cancer Society
According to rapid development of chemotherapy in advanced non-small cell lung cancer (NSCLC), the Japan Lung Cancer Society has been updated its own guideline annually since 2010. In this latest version, all of the procedure was carried out in accordance with grading of recommendations assessment, development and evaluation (GRADE) system. It includes comprehensive literature search, systematic review, and determination of the recommendation by multidisciplinary expert panel which consisted of medical doctors, pharmacists, nurses, statisticians, and patients from patient advocacy group. Recently, we have had various types of chemotherapeutic drugs like kinase inhibitors or immune-checkpoint inhibitors. Thus, the guideline proposes to categorize patients into three entities: (1) driver oncogene-positive, (2) PD-L150%, and (3) others. Based on this subgroup, 31 clinical questions were described. We believe that this attempt enables clinicians to choose appropriate treatment easier. Here, we report an English version of the Japan Lung Cancer Society Guidelines 2018 for NSCLC, stages IV.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据